Andreas Obermair

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8233897/publications.pdf

Version: 2024-02-01

230 papers

10,132 citations

53 h-index 46799 89 g-index

237 all docs

237 docs citations

times ranked

237

8695 citing authors

#	Article	IF	CITATIONS
1	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. New England Journal of Medicine, 2018, 379, 1895-1904.	27.0	1,274
2	Lymphedema after gynecological cancer treatment. Cancer, 2007, 109, 2607-2614.	4.1	303
3	Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncology, The, 2010, 11, 772-780.	10.7	296
4	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1224.	7.4	271
5	Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer, 2011, 21, 289-295.	2.5	239
6	Tumor Mismatch Repair Immunohistochemistry and DNA <i>MLH1</i> Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. Journal of Clinical Oncology, 2014, 32, 90-100.	1.6	195
7	Leiomyosarcoma of the Uterus: A Clinicopathologic Multicenter Study of 71 Cases. Gynecologic Oncology, 1999, 74, 196-201.	1.4	167
8	A Phase III Randomized Clinical Trial Comparing Laparoscopic or Robotic Radical Hysterectomy with Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer. Journal of Minimally Invasive Gynecology, 2008, 15, 584-588.	0.6	144
9	Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. American Journal of Clinical Nutrition, 2008, 87, 1678-1685.	4.7	144
10	Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. International Journal of Gynecological Cancer, 2005, 15, 319-324.	2.5	135
11	Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival., 1997, 74, 455-458.		132
12	Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecologic Oncology, 2012, 125, 263-270.	1.4	124
13	Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecologic Oncology, 2004, 92, 789-793.	1.4	121
14	Malnutrition among gynaecological cancer patients. European Journal of Clinical Nutrition, 2007, 61, 642-646.	2.9	119
15	Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. International Journal of Gynecological Cancer, 2005, 15, 319-324.	2.5	110
16	Prognostic Parameters in Endometrial Stromal Sarcoma: A Clinicopathologic Study in 31 Patients. Gynecologic Oncology, 2001, 81, 160-165.	1.4	109
17	Safety and Efficacy of Low Anterior en Bloc Resection as Part of Cytoreductive Surgery for Patients with Ovarian Cancer. Gynecologic Oncology, 2001, 83, 115-120.	1.4	108
18	Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecologic Oncology, 2015, 136, 87-93.	1.4	100

#	Article	IF	CITATIONS
19	Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: a cohort study. BMC Cancer, 2010, 10, 232.	2.6	99
20	A review of complications associated with the surgical treatment of vulvar cancer. Gynecologic Oncology, 2013, 131, 467-479.	1.4	98
21	Tumor angiogenesis in stage IB cervical cancer: Correlation of microvessel density with survival. American Journal of Obstetrics and Gynecology, 1998, 178, 314-319.	1.3	95
22	Vulvar cancer patients' quality of life: a qualitative assessment. International Journal of Gynecological Cancer, 2004, 14, 875-881.	2.5	95
23	LAP-VEGaS Practice Guidelines for Reporting of Educational Videos in Laparoscopic Surgery. Annals of Surgery, 2018, 268, 920-926.	4.2	93
24	Microvessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. International Journal of Cancer, 1995, 62, 126-131.	5.1	92
25	Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecologic Oncology, 2017, 146, 623-629.	1.4	92
26	Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients. Clinical Cancer Research, 2008, 14, 1692-1700.	7.0	91
27	Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 2012, 48, 1147-1153.	2.8	86
28	Serum HE4 as a prognostic marker in endometrial cancer â€" A population based study. Gynecologic Oncology, 2014, 132, 159-165.	1.4	86
29	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	1.2	85
30	Influence of Microvessel Density and Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression on Prognosis in Vulvar Cancer. Gynecologic Oncology, 1996, 63, 204-209.	1.4	84
31	Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. International Journal of Cancer, 2001, 95, 29-33.	5.1	84
32	Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer, 2000, 89, 1322-1328.	4.1	83
33	Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstetrics and Gynecology, 1998, 92, 360-363.	2.4	82
34	Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. International Journal of Cancer, 2002, 102, 237-243.	5.1	80
35	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2020, 222, 249.e1-249.e10.	1.3	78
36	Correlation of Vascular Endothelial Growth Factor Expression and Microvessel Density in Cervical Intraepithelial Neoplasia. Journal of the National Cancer Institute, 1997, 89, 1212-1217.	6.3	74

#	Article	IF	CITATIONS
37	Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. International Journal of Gynecological Cancer, 1999, 9, 383-386.	2.5	73
38	Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer, 2001, 92, 903-908.	4.1	72
39	Prognostic Importance of Preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: An Australian Multicenter Study. Journal of Clinical Oncology, 2005, 23, 5938-5942.	1.6	71
40	Total laparoscopic versus open surgery for stage 1 endometrial cancer: The LACE randomized controlled trial. Contemporary Clinical Trials, 2006, 27, 353-363.	1.8	67
41	Quality of life of women with lower-limb lymphedema following gynecological cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 287-297.	1.4	67
42	Color-coded and spectral Doppler flow in breast carcinomas â€" Relationship with the tumor microvasculature. Breast Cancer Research and Treatment, 1998, 47, 83-89.	2.5	64
43	Aspirin, nonsteroidal antiâ€inflammatory drugs, paracetamol and risk of endometrial cancer: A case–control study, systematic review and metaâ€analysis. International Journal of Cancer, 2013, 132, 1146-1155.	5.1	64
44	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. British Journal of Cancer, 1998, 77, 1870-1874.	6.4	61
45	Increased microvessel density in adenomyosis uteri. Fertility and Sterility, 2001, 75, 131-135.	1.0	59
46	Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. Cancer Letters, 2001, 164, 105-110.	7.2	59
47	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors*. Medical and Pediatric Oncology, 2001, 36, 601-604.	1.0	59
48	Improving treatment for obese women with early stage cancer of the uterus: Rationale and design of the levonorgestrel intrauterine device±Metformin±weight loss in endometrial cancer (feMME) trial. Contemporary Clinical Trials, 2014, 39, 14-21.	1.8	58
49	The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer, 1998, 83, 726-731.	4.1	57
50	The Western Australian Experience of the Use of en Bloc Resection of Ovarian Cancer with Concomitant Rectosigmoid Colectomy. Gynecologic Oncology, 2002, 84, 53-57.	1.4	57
51	Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. European Journal of Cancer, 2013, 49, 2717-2726.	2.8	57
52	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2020, 21, 851-860.	10.7	57
53	Survival of Australian women with invasive epithelial ovarian cancer: a populationâ€based study. Medical Journal of Australia, 2014, 201, 283-288.	1.7	56
54	Quality of life of women with lower limb swelling or lymphedema 3–5years following endometrial cancer. Gynecologic Oncology, 2014, 133, 314-318.	1.4	56

#	Article	IF	CITATIONS
55	Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecologic Oncology, 2007, 107, 124-129.	1.4	54
56	Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. BMC Cancer, 2011, 11, 389.	2.6	53
57	Vascular Endothelial Growth Factor Serum Concentrations in Ovarian Cancer. Obstetrics and Gynecology, 1998, 92, 360-363.	2.4	51
58	The functional assessment of cancer-vulvar: Reliability and validity. Gynecologic Oncology, 2005, 97, 568-575.	1.4	51
59	Risk of endometrial cancer for women diagnosed with HNPCCâ€related colorectal carcinoma. International Journal of Cancer, 2010, 127, 2678-2684.	5.1	50
60	The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. Gynecologic Oncology, 2018, 150, 99-105.	1.4	49
61	ER and PR expression and survival after endometrial cancer. Gynecologic Oncology, 2018, 148, 258-266.	1.4	49
62	Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Letters, 2002, 179, 197-203.	7.2	48
63	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 2020, 63, 417-431.	1.6	48
64	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clinical and Experimental Metastasis, 2014, 31, 135-147.	3.3	47
65	Angiogenesis in Vulvar Intraepithelial Neoplasia. Gynecologic Oncology, 1997, 64, 496-500.	1.4	46
66	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecologic Oncology, 2021, 161, 143-151.	1.4	46
67	Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Letters, 1999, 138, 175-182.	7.2	44
68	Feasibility and Safety of Total Laparoscopic Radical Hysterectomy. Journal of Minimally Invasive Gynecology, 2003, 10, 345-349.	1.2	44
69	Patterns of recurrence and disease-free survival in advanced squamous cell carcinoma of the vulva. Gynecologic Oncology, 2004, 95, 701-705.	1.4	44
70	Expression of MUC1 splice variants in benign and malignant ovarian tumours. International Journal of Cancer, 2002, 100, 166-171.	5.1	42
71	Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer, 2015, 15, 33.	2.6	41
72	Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Research, 1995, 15, 1549-51.	1.1	40

#	Article	IF	Citations
73	Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Letters, 1995, 94, 227-231.	7.2	39
74	Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecologic Oncology, 2013, 129, 467-471.	1.4	39
75	Development and validation of a recommended checklist for assessment of surgical videos quality: the LAParoscopic surgery Video Educational GuidelineS (LAP-VEGaS) video assessment tool. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1362-1369.	2.4	38
76	Clinical audit in gynecological cancer surgery: Development of a risk scoring system to predict adverse events. Gynecologic Oncology, 2009, 115, 329-333.	1.4	35
77	The utility of serum CAâ€125 in predicting extraâ€uterine disease in apparent earlyâ€stage endometrial cancer. International Journal of Cancer, 2012, 131, 885-890.	5.1	35
78	Nutrition interventions in patients with gynecological cancers requiring surgery. Gynecologic Oncology, 2017, 145, 192-199.	1.4	35
79	Endometrial cancer risk and survival by tumor MMR status. Journal of Gynecologic Oncology, 2018, 29, e39.	2.2	34
80	Impact of hysteroscopy on disease-free survival in clinically stage I endometrial cancer patients. International Journal of Gynecological Cancer, 2000, 10, 275-279.	2.5	34
81	Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Letters, 1998, 130, 69-76.	7.2	33
82	Vascular endothelial growth factor and its receptors in male fertility. Fertility and Sterility, 1999, 72, 269-275.	1.0	33
83	Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 2012, 48, 2155-2162.	2.8	33
84	Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. British Journal of Haematology, 2000, 110, 605-609.	2.5	32
85	Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 432-436.	2.8	32
86	Three-dimensional ultrasound of the female urethra: comparing transvaginal and transrectal scanning. Ultrasound in Obstetrics and Gynecology, 2001, 17, 425-430.	1.7	31
87	Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 504-507.	1.0	31
88	Expression and In Vitro Functions of the Ghrelin Axis in Endometrial Cancer. Hormones and Cancer, 2010, 1, 245-255.	4.9	31
89	Primary fallopian tube carcinoma: the Queensland experience. International Journal of Gynecological Cancer, 2001, 11, 69-72.	2.5	30
90	Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. International Journal of Gynecological Cancer, 2003, 13, 633-639.	2.5	30

#	Article	IF	CITATIONS
91	Validation of the FIGO 2009 Staging System for Carcinoma of the Vulva. International Journal of Gynecological Cancer, 2012, 22, 498-502.	2.5	30
92	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study. Gynecologic Oncology, 2013, 129, 310-317.	1.4	30
93	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic Oncology, 2017, 147, 381-387.	1.4	30
94	p53 Protein Overexpression: A Strong Prognostic Factor in Uterine Papillary Serous Carcinoma. Gynecologic Oncology, 1998, 71, 59-63.	1.4	29
95	CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. British Journal of Cancer, 1999, 81, 662-666.	6.4	29
96	Novel MUC1 Splice Variants Are Expressed in Cervical Carcinoma. Gynecologic Oncology, 2001, 83, 343-347.	1.4	29
97	Primary Bartholin gland carcinoma: a report of seven cases. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2001, 41, 78-81.	1.0	29
98	Total Laparoscopic Hysterectomy with a Transvaginal Tube. Journal of Minimally Invasive Gynecology, 2004, 11, 79-82.	1.2	29
99	A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecologic Oncology, 2007, 104 , $607-611$.	1.4	29
100	Elderly patients with stage III or IV ovarian cancer: should they receive standard care?. International Journal of Gynecological Cancer, 2008, 18, 896-907.	2.5	29
101	The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. BMJ Open, 2013, 3, e001884.	1.9	29
102	Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer Oncology Reports, 2000, 7, 639-44.	2.6	29
103	Serum Concentrations of Endostatin in Patients with Vulvar Cancer. Gynecologic Oncology, 1999, 74, 151-152.	1.4	28
104	Expression of mucins and cytokeratins in ovarian cancer cell lines. Cancer Letters, 1999, 145, 133-141.	7.2	28
105	The urethra during pelvic floor contraction: observations on three-dimensional ultrasound. Obstetrics and Gynecology, 2002, 100, 796-800.	2.4	28
106	Impact of Videotaped Information on Frequency and Confidence of Breast Self-Examination. Breast Cancer Research and Treatment, 2002, 73, 37-43.	2. 5	28
107	Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801). Gynecologic Oncology, 2012, 126, 36-40.	1.4	28
108	Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis. International Journal of Gynecological Cancer, 2018, 28, 529-538.	2,5	28

#	Article	IF	Citations
109	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 647-655.	2.5	28
110	Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecologic Oncology, 2012, 125, 520-525.	1.4	27
111	Predicting positive and negative impacts of cancer among longâ€ŧerm endometrial cancer survivors. Psycho-Oncology, 2013, 22, 1963-1971.	2.3	27
112	The Impact of Positive Peritoneal Washings and Serosal and Adnexal Involvement on Survival in Patients with Stage IIIA Uterine Cancer. Gynecologic Oncology, 2002, 86, 269-273.	1.4	26
113	Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 2013, 132, 2876-2883.	5.1	26
114	Prognostic significance of tumor angiogenesis in endometrial cancer. Obstetrics and Gynecology, 1999, 93, 367-371.	2.4	25
115	Impaired Quality of Life in Patients Commencing Radiotherapy for Cancer. Strahlentherapie Und Onkologie, 2004, 180, 78-83.	2.0	25
116	Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. Gynecologic Oncology Research and Practice, 2016, 3, 1.	3.6	25
117	Extracellular Vesicle-Associated miRNAs and Chemoresistance: A Systematic Review. Cancers, 2021, 13, 4608.	3.7	25
118	Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. European Journal of Cancer, 2003, 39, 1129-1140.	2.8	24
119	Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecologic Oncology, 2004, 92, 175-179.	1.4	24
120	Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Archives of Gynecology and Obstetrics, 2005, 271, 316-319.	1.7	24
121	Postoperative analgesic requirements - total laparoscopic hysterectomy versus vaginal hysterectomy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 140-143.	1.0	23
122	Evaluation of Tumor-Free Distance and Depth of Myometrial Invasion as Prognostic Factors for Lymph Node Metastases in Endometrial Cancer. International Journal of Gynecological Cancer, 2010, 20, 1217-1221.	2.5	23
123	Thrombosis with paclitaxel. Lancet, The, 1994, 343, 727.	13.7	22
124	The anatomy of complications workshop: an educational strategy to improve the training and performance of fellows in gynecologic oncology. Gynecologic Oncology, 2004, 94, 769-773.	1.4	22
125	Depression, anxiety and body image after treatment for invasive stage one epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2009, 49, 660-666.	1.0	22
126	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22

#	Article	IF	CITATIONS
127	The influence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma., 1998, 82, 689-696.		21
128	Incidence of Anaemia in Breast Cancer Patients Receiving Adjuvant Chemotherapy. Breast Cancer Research and Treatment, 2003, 79, 347-353.	2.5	21
129	Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1811-1823.	2.5	21
130	The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer, 1998, 83, 726-31.	4.1	21
131	Influence of Tumoral Microvessel Density on the Recurrence-Free Survival in Human Breast Cancer: Preliminary Results. Oncology Research and Treatment, 1994, 17, 44-49.	1.2	20
132	Total laparoscopic hysterectomy: The Brisbane learning curve. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 65-69.	1.0	20
133	Epidural analgesia is associated with an increased incidence of postoperative complications in patients requiring an abdominal hysterectomy for early stage endometrial cancer. Gynecologic Oncology, 2013, 131, 423-429.	1.4	20
134	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecologic Oncology, 2020, 159, 179-186.	1.4	20
135	A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecological Cancer, 2021, 31, 1595-1601.	2.5	20
136	Parity as an Independent Prognostic Factor in Malignant Mixed Mesodermal Tumors of the Endometrium. Gynecologic Oncology, 1997, 64, 121-125.	1.4	19
137	Survey of surgical skills of RANZCOG trainees. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2009, 49, 84-92.	1.0	19
138	The impact of riskâ€reducing hysterectomy and bilateral salpingoâ€oophorectomy on survival in patients with a history of breast cancerâ€"A populationâ€based data linkage study. International Journal of Cancer, 2014, 134, 2211-2222.	5.1	19
139	Nomogram to Predict the Probability of Relapse in Patients Diagnosed With Borderline Ovarian Tumors. International Journal of Gynecological Cancer, 2013, 23, 264-267.	2.5	18
140	Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study Gynecologic Oncology, 2020, 158, 375-381.	1.4	18
141	Vascular endothelial growth factor serum levels in pregnancy and preeclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 77-78.	2.8	17
142	The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 651-658.	1.0	16
143	A healthy lifestyle and survival among women with ovarian cancer. International Journal of Cancer, 2020, 147, 3361-3369.	5.1	16
144	In vitro cytokine and prostaglandin production by amnion cells in the presence of bacteria. American Journal of Obstetrics and Gynecology, 1997, 176, 981-984.	1.3	15

#	Article	IF	CITATIONS
145	Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 1935-1942.	2.5	15
146	Sentinel lymph node mapping in endometrial cancer – areas where further research is needed. International Journal of Gynecological Cancer, 2020, 30, 283-284.	2.5	15
147	Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E305-E313.	3.5	14
148	Long-term quality of life outcomes of women treated for early-stage endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 530-536.	2.5	14
149	RANDOMIZED TRIAL OF SKIN CLOSURE AFTER LAPAROTOMY FOR GYNAECOLOGICAL SURGERY. ANZ Journal of Surgery, 2007, 77, 460-463.	0.7	13
150	Consideration for safe and effective gynaecological laparoscopy in the obese patient. Archives of Gynecology and Obstetrics, 2015, 292, 135-141.	1.7	13
151	Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trial. Gynecologic Oncology, 2015, 137, 516-522.	1.4	13
152	Lower preoperative quality of life increases postoperative risk of adverse events in women with endometrial cancer: Results from the LACE trial. Gynecologic Oncology, 2015, 137, 102-105.	1.4	13
153	A Bioimpedance Spectroscopy-Based Method for Diagnosis of Lower-Limb Lymphedema. Lymphatic Research and Biology, 2020, 18, 101-109.	1.1	13
154	Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment) Tj ETQq0 0 0	rgBIT4/Ove	rlo ck 10 Tf 50
155	Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma. Gynecologic Oncology, 2008, 110, 280-285.	1.4	12
156	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 2011, 120, 179-184.	1.4	12
157	The relative risk of second primary cancers in Austria's western states: a retrospective cohort study. BMC Cancer, 2017, 17, 699.	2.6	12
158	Physical activity trajectories following gynecological cancer: results from a prospective, longitudinal cohort study. International Journal of Gynecological Cancer, 2020, 30, 1784-1790.	2.5	11
159	Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study. International Journal of Gynecological Cancer, 2021, 31, 553-561.	2.5	11
160	The Lymphedema Evaluation in Gynecological cancer Study (LEGS): design of a prospective, longitudinal, cohort study. Cancer Research Frontiers, 2015, 1, 104-118.	0.2	11
161	Austrian women's attitudes toward and knowledge of breast self-examination. Journal of Cancer Education, 2000, 15, 91-4.	1.3	11
162	Influence of delayed diagnosis on established prognostic factors in endometrial cancer. Anticancer Research, 1996, 16, 947-9.	1,1	11

#	Article	IF	Citations
163	The overlay autogenous tissue (OAT) patch to control major intraoperative vascular injury in an ovine model. Gynecologic Oncology, 2004, 94, 560-563.	1.4	10
164	Vulval Keratoacanthoma: a case report. Gynecologic Oncology, 2005, 97, 674-676.	1.4	10
165	How to train practising gynaecologists in total laparoscopic hysterectomy: protocol for the stepped-wedge IMAGINE trial. BMJ Open, 2019, 9, e027155.	1.9	10
166	Quality of life following minimally invasive hysterectomy compared to abdominal hysterectomy: A metanalysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 206-212.	1.1	10
167	Hospital costs associated with adverse events in gynecological oncology. Gynecologic Oncology, 2011, 121, 70-75.	1.4	9
168	Knowledge, Attitudes and Referral Patterns of Lynch Syndrome: A Survey of Clinicians in Australia. Journal of Personalized Medicine, 2014, 4, 218-244.	2.5	9
169	Normative Interlimb Impedance Ratios: Implications for Early Diagnosis of Uni- and Bilateral, Upper and Lower Limb Lymphedema. Lymphatic Research and Biology, 2018, 16, 559-566.	1.1	9
170	Challenges and controversies in the conservative management of uterine and ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2019, 55, 93-108.	2.8	9
171	Patient-Reported Experiences After Hysterectomy: A Cross-Sectional Study of the Views of Over 2300 Women. Journal of Patient Experience, 2020, 7, 372-379.	0.9	9
172	The control of severe intraoperative bleeding using an overlay autogenous tissue (OAT) patch: case reports. Gynecologic Oncology, 2004, 94, 564-566.	1.4	8
173	Laparoscopy in the treatment of ovarian tumours of low malignant potential. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 438-444.	1.0	8
174	Paucity of data evaluating patient centred outcomes following sentinel lymph node dissection in endometrial cancer: A systematic review. Gynecologic Oncology Reports, 2021, 36, 100763.	0.6	8
175	Vascular endothelial growth factor serum levels in pregnancy and preeclampsia. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 77-78.	2.8	7
176	Wrigley forceps to deliver a bulky uterus following a total laparoscopic hysterectomy for endometrial cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 444-445.	1.0	7
177	Differences in Epidural and Analgesic Use in Patients with Apparent Stage I Endometrial Cancer Treated by Open versus Laparoscopic Surgery: Results from the Randomised LACE Trial. Minimally Invasive Surgery, 2013, 2013, 1-5.	0.5	7
178	Pelvic floor functional outcomes after total abdominal vs total laparoscopic hysterectomy for endometrial cancer. American Journal of Obstetrics and Gynecology, 2018, 218, 419.e1-419.e14.	1.3	7
179	Surgical approach to hysterectomy and barriers to using minimally invasive methods. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, 690-695.	1.0	7
180	Incidence of adverse events, preventability and mortality in gynaecological hospital admissions: A systematic review and metaâ€analysis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 195-200.	1.0	7

#	Article	IF	CITATIONS
181	Advanced cytoreductive surgery: Asia Pacific perspective. Gynecologic Oncology, 2009, 114, S15-S21.	1.4	6
182	Potential hospital cost-savings attributed to improvements in outcomes for colorectal cancer surgery following self-audit. BMC Surgery, 2010, 10, 4.	1.3	6
183	Factors influencing women's decision making in hysterectomy. Patient Education and Counseling, 2018, 101, 504-510.	2.2	6
184	The Prevalence, Incidence, and Quality-of-Life Impact of Lymphedema After Treatment for Vulvar or Vaginal Cancer. Rehabilitation Oncology, 2018, 36, 48-55.	0.5	6
185	Anxiety and depression in patients with early stage endometrial cancer: A longitudinal analysis from before surgery to 6-month post-surgery. Journal of Psychosocial Oncology Research and Practice, 2019, 1, e13.	0.5	6
186	Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. Gynecologic Oncology, 2020, 158, 47-53.	1.4	6
187	The Urethra During Pelvic Floor Contraction. Obstetrics and Gynecology, 2002, 100, 796-800.	2.4	5
188	The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study. Journal of Ovarian Research, 2012, 5, 11.	3.0	5
189	Reply to J. Moline et al. Journal of Clinical Oncology, 2014, 32, 2278-2279.	1.6	5
190	Realâ€world surgical outcomes of a gelatinâ€hemostatic matrix in women requiring a hysterectomy: a matched case–control study. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 1008-1014.	2.8	5
191	How many patients enter endometrial cancer surgery with psychotropic medication prescriptions, and how many receive a new prescription perioperatively?. Gynecologic Oncology, 2019, 152, 339-345.	1.4	5
192	The impact of team familiarity on surgical outcomes in gynaecological surgery. Journal of Obstetrics and Gynaecology, 2020, 40, 290-292.	0.9	5
193	The use of CAM products, practices, and practitioners by long-term endometrial cancer survivors in Australia. Supportive Care in Cancer, 2020, 28, 5479-5489.	2.2	5
194	Does hysteroscopy facilitate tumor cell dissemination?. Cancer, 2000, 88, 139-143.	4.1	5
195	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 2021, 32, e95.	2.2	5
196	Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood. Oncology Research, 1999, 11, 367-73.	1.5	5
197	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.	2.5	4
198	International Journal of Gynecological Cancer, 2022, 32, 560-565. Women with self-reported lower-limb lymphedema after treatment for gynecological cancers: are they more likely to self-report psychosocial symptoms and less likely to use services?. Journal of Community and Supportive Oncology, 2015, 13, 55-61.	0.1	4

#	Article	IF	Citations
199	Preoperative serum CA125 in surgical stage 1 epithelial ovarian cancer. Gynecologic Oncology, 2007, 107, 357-358.	1.4	3
200	Feasibility and Outcomes of Ureteroureterostomy and Extravesical Ureteroneocystostomy as Part of Radical Surgery for Infiltrating Gynecologic Disease. International Journal of Gynecological Cancer, 2013, 23, 1139-1145.	2.5	3
201	Incidence, Risk Factors, and Estimates of a Woman's Risk for Developing Secondary Lower Limb Lymphedema and Lymphedema-Specific Supportive Care Needs in Women Treated for Endometrial Cancer. Obstetrical and Gynecological Survey, 2015, 70, 176-177.	0.4	3
202	Do breast cancer survivors benefit from prophylactic removal of uterus and ovaries? A population-based data linkage replication study. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 68-78.	1.1	3
203	Obesity in total laparoscopic hysterectomy for early stage endometrial cancer: health gain and inpatient resource use. International Journal for Quality in Health Care, 2019, 31, 283-288.	1.8	3
204	Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study). Cancers, 2021, 13, 2378.	3.7	3
205	Fertility-sparing management of early-stage endometrial cancer in reproductive age women: current treatment outcomes and future directions. International Journal of Gynecological Cancer, 2021, 31, 1506-1507.	2.5	3
206	Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study. Gynecologic Oncology Reports, 2022, 39, 100914.	0.6	3
207	Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles. Journal of Clinical Oncology, 2022, 40, 2378-2388.	1.6	3
208	Prognostic significance of tumor angiogenesis in primary fallopian tube cancer. Cancer Letters, 1999, 141, 179-186.	7.2	2
209	Correlation of the serum concentration of vascular endothelial growth factor (VEGF) and hemoglobin levels in patients with epithelial ovarian cancer. Annals of Oncology, 1999, 10, 998.	1.2	2
210	Histopathologic Correlation of High-Resolution Magnetic Resonance Imaging of Human Cervical Tissue Samples at 3 Tesla. Investigative Radiology, 2002, 37, 381-385.	6.2	2
211	Lynch Syndrome in Women Less Than 50 Years of Age With Endometrial Cancer. Obstetrics and Gynecology, 2008, 112, 943.	2.4	2
212	Laparoscopy or laparotomy for early endometrial cancer? – Authors' reply. Lancet Oncology, The, 2010, 11, 1022-1023.	10.7	2
213	Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in Australia. BMJ Quality and Safety, 2013, 22, 878-878.	3.7	2
214	Comment on â€~External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours'. British Journal of Cancer, 2014, 111, 2375-2375.	6.4	2
215	Germline BRCA variants, lifestyle and ovarian cancer survival. Gynecologic Oncology, 2022, , .	1.4	2
216	Re: Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage 1. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 447-447.	1.0	1

#	Article	IF	CITATIONS
217	Clinical Audit in Gynecological Cancer Surgery: Development of a Risk Scoring System to Predict Adverse Events. Obstetrical and Gynecological Survey, 2010, 65, 93-94.	0.4	1
218	Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumours using biomarkers or the ROMA algorithm. Gynecologic Oncology, 2013, 130, 400.	1.4	1
219	Endometrial polyp and endometriosis with atypical stromal cells. Pathology, 2013, 45, 191-193.	0.6	1
220	Can the use of quality assurance tools reduce the impact of surgical complications on the wellâ€being of obstetricians and gynaecologists in <scp>A</scp> ustralia and <scp>N</scp> ew <scp>Z</scp> ealand?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 30-35.	1.0	1
221	Cost-Efficiency of Robotic Surgery. International Journal of Gynecological Cancer, 2016, 26, 992-993.	2.5	1
222	Lymphatic microvessel density as a novel prognostic factor in earlyâ€stage invasive cervical cancer. International Journal of Cancer, 2001, 95, 29-33.	5.1	1
223	Vessel Invasion Predicts Early Recurrence in Breast Cancer: Preliminary Results. Oncology Research and Treatment, 1993, 16, 434-439.	1.2	O
224	Erratum to "Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin–cisplatin with cyclophosphamide-cisplatin― European Journal of Cancer, 2004, 40, 627.	2.8	0
225	Vaginal cuff dehiscence associated with laparoscopic hysterectomy. Gynecological Surgery, 2013, 10, 227-227.	0.9	O
226	Survival After Laparoscopic vs Abdominal Hysterectomyâ€"Reply. JAMA - Journal of the American Medical Association, 2017, 318, 574.	7.4	0
227	All-cause death in young women with endometrial cancer who receive progesterone therapy. American Journal of Obstetrics and Gynecology, 2018, 219, 119.	1.3	0
228	Can a symptom checklist improve the triage of patients following successful endometrial cancer treatment?. Gynecologic Oncology Reports, 2020, 33, 100604.	0.6	0
229	Vaginal vault smear cytology in detection of recurrence after hysterectomy for early cervical cancer. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003302.	2.5	0
230	Are endometrial cancer clinical practice management guidelines sufficiently consumer centric?. International Journal of Gynecological Cancer, 2022, , ijgc-2022-003580.	2.5	0